Yahoo Finance The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants
For Immediate Releases
Chicago, IL – May 21, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Inc. UNH, Danaher Corp. DHR and Abbott Laboratories ABT and Ark Restaurants Corp. ARKR.
Top Stock Reports for UnitedHealth, Danaher & Abbott Labs
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc., Danaher Corp. and Abbott Laboratories, as well as a micro-cap stock Ark Restaurants Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
UnitedHealth shares have outperformed the Zacks Medical - HMOs industry over the past year (+10.8% vs. +10.6%). The company’s top line remains poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. The company’s solid health services segment provides diversification benefits.
The Government business remains well-poised for growth in the future. Adjusted net earnings per share are anticipated to be in the $27.5-$28.00 band in 2024, higher than the 2023 reported figure of $25.12. A sturdy balance sheet enables business investments and prudent deployment of capital via share repurchases and dividend payments.
However, membership in its global business continues to be a concern. High operating costs due to rising medical expenses are hurting margins. As such, the stock warrants a cautious stance.
(You can read the full research report on UnitedHealth here >>>)
Shares of Danaher have outperformed the Zacks Diversified Operations industry over the past year (+30.7% vs. +11.7%). The company’s Life Sciences unit is witnessing support from stable demand in the academic and applied markets. The segment has been witnessing positive responses toward its new products. The company’s commitment to return value to shareholders is encouraging.
Synergies from the Abcam acquisition bolster the company’s growth. Through its DBS initiatives, it has been able to reduce the impact of supply-chain constraints and inflationary pressures.
However, Danaher is plagued by weakness in the Biotechnology unit due to decreased demand in the bioprocessing business. Softness in the funding environment and lower underlying activity levels are affecting the high-growth markets’ performance. High debt levels may raise its financial obligations and drain its profitability. Given its international exposure, forex woes are weighing on its top line.
(You can read the full research report on Danaher here >>>)
Abbott shares have gained +3.2% over the past six months against the Zacks Medical - Products industry’s gain of +11.7%. The company’s pipeline is generating several new growth prospects, which will help sustain the positive momentum and contribute to the strong growth projection in 2024.
Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. EPD's impressive stretch of strong performance stems from the company’s unique business model. Freestyle Libre CGM device is also on a great trajectory, continually outpacing market growth.
Within Nutrition, after a period of hiccups, Abbott has finally reestablished itself as the market leader in the infant formula business, underscoring strong customer confidence in the company's products. However, the slump in COVID-19 testing-related sales is hurting Abbott’s overall growth. Tough macro conditions also pose a concern for its operations.
(You can read the full research report on Abbott here >>>)
Shares of Ark Restaurants have underperformed the Zacks Retail - Restaurants industry over the past six months period (-3.8% vs. +1.6%). This microcap company of market capitalization of less than $100 million is facing rising operational costs in food and supplies, pressing margins. The company's sensitivity to economic shifts threatens dining spending, impacting revenues.
Lease obligations and the need to refresh premises could negatively impact cash flow. Shifts in consumer preferences and weather can disrupt operations. Reliance on key locations, rising labor and regulatory costs, competition, and cybersecurity risks pose threats.
Yet, Ark Restaurants' financial management, revenue resilience in the fiscal first quarter of 2024, diverse portfolio, and strategic expansion signal growth potential. Investments in infrastructure and operational efficiency aim at profitability. The company could potentially capitalize on the food service industry, which is projected to witness a robust expansion.
(You can read the full research report on Ark Restaurants here >>>)
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Danaher Corporation (DHR) : Free Stock Analysis Report
Ark Restaurants Corp. (ARKR): Free Stock Analysis Report
